Sequence-resolved DNA cleavage
Biochemical assay · End-labeled 128-bp Sal I–Dra II pBR322 DNA fragment [1]
Dynemicin produced sequence-dependent cleavage in the NADPH system.
| Endpoint | Reported result | Reference |
|---|---|---|
| DNA strand scission | Qualitative cleavage pattern Preferred sites were 3′ of purines, including 5′-AG, -GC and -AT; intact-DNA lanes were included. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μM dynemicin; 5 mM NADPH
- Exposure duration
- 5 h
- Method
- 37°C; sequencing-gel analysis
- Co-treatment
- NADPH activation; not a drug-combination efficacy experiment.
- Reported limits
- Drug solvent and replication/uncertainty not specified for Fig. 2.
Methods and source locations
Compound reported in the paper: Dynemicin A; Compound label in the paper: Dynemicin
Evidence concerns the authors’ material, without validation of an Adooq lot or its enantiomeric purity.
pp. 3831–3832, assay/sequence methods and Fig. 2
DNA strand scission: Denaturing sequencing gel; both end-label orientations. — p. 3832, Fig. 2 and Sequence-Specific DNA Cleavage